Last checked at 5 Jul 2012 14:45
5 July 2012 |
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Directors' shareholdings
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that the following Directors purchased ordinary shares of 5 pence each ("Ordinary Shares").
Director | Date purchased | Price purchased | Shares purchased | Resultant holding | % of issued share capital |
Chris Meredith, Chief Executive Officer | 5 July 2012 | 67.63p | 4,393 | 1,136,769 | 0.6 |
Mary Tavener, Group Finance Director | 4 July 2012 | 66.50p | 7,500 | 2,081,651 | 1.2 |
- ends -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director | |
Tavistock Communications | Tel: +44 (0) 20 7920 3150 |
John West / Chris Munden / Andrew Dunn | |
Investec Bank plc | Tel: +44 (0) 20 7597 5970 |
Gary Clarence / Daniel Adams / Patrick Robb |
About Advanced Medical Solutions Group plc - see www.admedsol.com
Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. These products are sold in countries across the globe either directly or through strategic partners and distributors.
AMS's advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids, provide an optimal environment for healing to occur and, in the case of silver alginates, include a safe and effective broad-spectrum anti-microbial agent for infection control. AMS's advanced woundcare products are sold globally on an Original Equipment Manufacturer basis and, in the UK, direct to the NHS under the ActivHeal® brand.
AMS's wound closure and sealants products are based on cyanoacrylate adhesive ("superglue") technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites. AMS's wound closure and sealants products are primarily sold under the LiquiBand® brand via a network of distributors.
In December 2011, AMS acquired RESORBA, a German based woundcare and wound closure business. RESORBA is a 75 year old manufacturer and distributor of sutures and collagen products for surgical disciplines, with direct sales capabilities from sites in Germany, the Czech Republic and Russia, targeting surgeons working in hospitals and private practices, and oral surgery. RESORBA has a range of its own technologies and brands, and also distributes a range of complementary, third-party products, including AMS's LiquiBand® tissue adhesive, which it has distributed in Germany for the previous eight years.